COVID-19 Pandemic: Laboratory Diagnostic Methods and Related Biosafety Regulations

Main Article Content

Isma’il Rabi’u
Sheriffdeen Bale Issa
Muhyiddeen Muazu


The repeated spread, loss of lives and melt down of the global economy as a result of the outbreak of Coronavirus Disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is posing a great challenge to the global health and economy. As of the first week of September, the disease has affected about 216 countries with nearly 900,000 deaths. In Nigeria, the total deaths recorded have exceed one thousand. The rapid, early and accurate laboratory diagnosis of SARS-CoV-2 is one of the key roles in fighting against the disease. There is the problem of the insufficient sensitivity of a single means to detect the virus and the co-infection with other viruses, creating chance for a high false-negative result. In addition to molecular tests (which are the basis for confirmation of SARS-CoV-2) and Genomic sequencing, serological tests can be used as an additional test in other to boycott false negative results, and play an increasingly important role in understanding the epidemiology of the virus, identify people at risk of contracting the disease, and patients at risk for severe complications. This review will discuss the different laboratory diagnostic methods for SARS-CoV-2, the sample of choice and related biosafety regulations.

Covid-19, “Biosafety”s: coronavirus, genomic sequencing, Nigeria, severe acute respiratory syndrome coronavirus-2, serological tests.

Article Details

How to Cite
Rabi’u, I., Issa, S. B., & Muazu, M. (2021). COVID-19 Pandemic: Laboratory Diagnostic Methods and Related Biosafety Regulations. International Journal of Research and Reports in Hematology, 4(1), 1-19. Retrieved from
Review Article


Chinese Centre for Disease Control and Prevention, (CCDCP). Report of the WHO China Joint Mission on Coronavirus Disease 2019 (COVID-19), 2020;16-24. February 2020

Lippi G, Salvagno GL, Pegoraro M et al. Assessment of immune response to SARS CoV-2 with fully-automated MAGLUMI 2019-nCoV IgG and Ig Mchemiluminescence immunoassays. Clin Chem Lab Med. 2020b.
DOI: 10.1515/cclm- 2020-0473.

Mummed Y. Molecular Targets for COVID-19 Drug Development: Enlightening Nigerians about the pandemic and future treatment. Biosafety and Health; 2020.
Available: access date:17th/08/2020

World Health Organization, (WHO). Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020. Geneva: WHO; 2020.
Available: 2020f access date: 15th/07/2020

World Health Organization, (WHO). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization; 2020a.

Ahmad S, Abdul HS, Ali S, Mumtaz A, Shruti M. A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. Eurasian Journal of Medicine and Oncology. 2020;4(2):116–125,
DOI: 10.14744/ejmo.2020;90853

Lippi G., Mattiuzzi C., Bovo C, Plebani M. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed. 2020;91(2):000-000.
DOI: 10.23750/abmv91i2.9548

Nigeria Centre for Disease Control (NCDC). COVID-19 Situation Report, Situation Report 188, Data as Reported and Accurate by NCDC as at midnight 3rd September 2020. 2020b; Thursday.

Nigeria Centre for Disease Control (NCDC). COVID-19 Situation report, situation report 189, data as reported and accurate by NCDC as at midnight 4th September 2020Friday. 2020a.

Nigeria Centre for Disease Control (NCDC). COVID-19 Situation report, situation report 186, data as reported and accurate by NCDC as at midnight 1st September 2020Tuesday. 2020c.

Nigeria Centre for Disease Control (NCDC). COVID-19 Situation report, situation report 93, data as reported and accurate by NCDC as at midnight 1st May, 2020 Sunday; 2020d.

Nigeria Centre for Disease Control (NCDC). COVID-19 Situation report, situation report 154, data as reported and accurate by NCDC as at midnight 31st July 2020 Friday; 2020e.

Padhi A, Swatantra K, Ekta G, Shailendra KS. Laboratory diagnosis of novel coronavirus disease 2019 (COVID-19) Infection. Chapter 9: Coronavirus Disease 2019 (COVID-19), Medical Virology: from Pathogenesis to Disease Control; 2020.

Yuanyuan X, Zhong P, Caixia T, Xiujuan M, Xun H, Anhua W, Chunhui L. Diagnostic options for coronavirus disease 2019 (COVID-19). Infection Control & Hospital Epidemiology.2020.
DOI: 10.1017/ice.2020.168

Kumar R, Suman N, Samander K, Sanjay M. COVID-19 diagnostic approaches: different roads to the same destination. Virus Dis. 2020;31(2):97–105.

Li C, Chengxue Zhaoa, Jingfeng Baoa, Bo Tangb, Yunfeng Wangc, Bing Gu. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). Clinica Chimica Acta.2020;35-46. SARS

Fang FC, Samia NN, Alexander LG. The Laboratory Diagnosis of Coronavirus Disease 2019— Frequently Asked Questions. Clinical Infectious Disease; 2020.
DOI: 10.1093/cid/ciaa742

D’Cruz, Roshan J., Arthur W. Currier, Valerie B. Sampson. Laboratory testing methods for novel severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2). Frontiers in Cell and Developmental Biology. 2020;468.
DOI: 10.3389/fcell.2020.00468

Centers for Disease Control and Prevention CDC. Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID 19). Coronavirus Disease 2019 (COVID-19) Lab Biosafety Guidelines; 2019.
Available: 2020b. accessed date 24 july, 2020

World Health Organization, (WHO). WHO-reference-laboratories-providing confirmatory-testing-for-covid-19.pdf. Accessed March 22, 2020. 2020c.

Chu DKW, Pan Y, Cheng S MS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019- nCoV) causing an outbreak of pneumonia. Clin Chem. 2020;66:549–555.
DOI: 10.1093/clinchem/hvaa029

Chun L, Ren L. Recent progress on the diagnosis of 2019 Novel Coronavirus. Transbound Emerg Dis. 2020;67:1485–1491.

Broughton JP, Deng W, Fasching CL, Singh J, Chiu CY, Chen JS. A protocol for rapid detection of the novel coronavirus SARS-CoV-2 using CRISPR diagnostics: SARS-CoV-2 DETECTR; 2019.

Available: https://mammo ds/2020/02/Aproto col-for-rapid -detec tion-of-the-2019-novel -coronaviru s-SARSCoV- 2 using -CRISP R-diagnostic s-SARS-CoV-2-DETEC TR.pdf. 2020

Centre for Disease Control and Prevention CDC. Tests for COVID-19; 2019.
Available: coronavirus/2019-ncov/about/testing.html. 2020a. Last accessed, April 15

World Health Organization, (WHO). Advice on the use of point-of-care immunodiagnostic tests for COVID-19, Scientific brief of 8 April 2020; 2020d.

Haveri A, Smura T, Kuivanen S, et al. Serological and molecular findings during SARS CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020;25(11).

Jin Y, Wang M, Zuo Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis. 2020 Apr 3. Pii: S1201 2020;9712(20):30198-3.
DOI:10.1016/j.ijid.2020.03.065.(Epub ahead of print).

Lin Q, Zhu L, Ni Z, et al. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection. J MicrobiolImmunol Infect. 2020; pii: S1684 1182(20)30075-X.
DOI: 10.1016/j.jmii.2020.03.015.(Epub ahead of print)

Mboowa G. Current and emerging diagnostic tests available for the novel COVID-19 global pandemic. AAS Open Research.2020;3:8.
Available: (, access date: 25 june 2020

National Health Commission of the Peoples Republic of China (NHCPRC). The diagnostically and therapeutic scheme for COVID-19(trial version 7); 2020.
Available: html. Published 2020. Accessed July 24, 2020.

World Health Organization, (WHO). Coronavirus disease (COVID-19) Technical guidance: Laboratory testing for 2019-nCoV in humans; 2019.
Available: diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance. 2020e. access address: 15th/07/2020

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet. 2020;395(10224):565–574.

Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019- nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020.

World Health Organization, (WHO). Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Geneva: WHO; 2020b. [accessed 27 March 2020]. Available: transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations.
Richmond JY. The 1, 2, 3's of Biosafety Levels; 2020.
Accessed 24 july, 2020

Chosewood LC, Wilson DE, eds. Biosafety in Microbiological and Biomedical Laboratories (5th ed.). Centers for Disease Control and Prevention. 2020. ISBN 0-1608-5042-8.

United States Department of Health and Human Services (USDHHS). Section IV-Laboratory Biosafety Level Criteria. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. 2016;30–59.

United States Army Medical Research Institute of Infectious Diseases (USAMRIID); 2020.
Available: access date: 4th/07/2020

Germfree / Product Lines / Life Science Labs / BSL-3 Ag & BSL-4 Capabilities.
Available: access date:4th/072020